Research
Hormonal
Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.
If you have obesity or overweight with related health issues, daily liraglutide injections, combined with diet and exercise, can lead to moderate weight loss (around 5 kg) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated. Note that it may be less effective than other options like semaglutide.
StrongQualifiesHIGH confidence
Лираглутид 3,0 мг обеспечивает эффективную и устойчивую потерю массы тела [139], однако менее выраженную, чем семаглутид 2,4 мг (по данным метаанализа, применение семаглутида 2,4 мг приводило к средней потере массы тела на 12,47 кг, лираглутида 3,0 мг -5,24 кг [140]
Why this rating
Based on cited meta-analyses.
Source
Overweight and obesity in metabolic syndrome
С. В. Недогода et al. · Russian Journal of Cardiology · 2025
DOI 10.15829/1560-4071-2025-6535
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.Strong
- Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →